Evidence map›Paper›PMID 40759784›Full record

Observational studyEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience.

Antonella Loperfido, Carlo Cavaliere, Andrea Ciofalo, Marcella Bugani, Elona Begvarfaj, Stefano Millarelli, Gianluca Bellocchi, Marco de Vincentiis, Simonetta Masieri

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Modifying the course of asthma: mechanisms and strategies for clinical remission.Current opinion in allergy and clinical immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonella Loperfido *Otolaryngology Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy. aloperfido@scamilloforlanini.rm.it.ORCID http://orcid.org/0000-0002-7174-8126
Carlo Cavaliere *Department of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0002-0378-8935
Andrea CiofaloDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-1468-459X
Marcella BuganiDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.
Elona BegvarfajDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0002-6960-2822
Stefano MillarelliOtolaryngology Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy.
Gianluca BellocchiOtolaryngology Unit, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, 00152, Italy.ORCID http://orcid.org/0000-0001-5341-3309
Marco de VincentiisDepartment of Sense Organs, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0002-1990-7820
Simonetta MasieriDepartment of Oral and Maxillofacial Sciences, Sapienza University, Rome, 00185, Italy.ORCID http://orcid.org/0000-0003-0423-9505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBiologics targeting the underlying inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) not only alleviate symptoms but also provide potential disease-modifying effects. This has redefined treatment goals in CRSwNP, emphasizing the concept of achieving disease remission as proposed by the EPOS2020/EUFOREA expert panel. Remission in CRSwNP is defined as sustained control for at least 12 months, along with the absence of active disease as assessed by nasal endoscopy. The purpose of this study was to identify patients with severe CRSwNP who achieved disease remission during the first two years of Dupilumab treatment.

methodsThis real-life, observational, retrospective study evaluated the effectiveness and safety of Dupilumab in patients with severe, uncontrolled CRSwNP over two years. Remission was assessed taking into account the latest EPOS2020/EUFOREA expert panel and currently available expert opinion on the topic. Data were collected at baseline and after 1, 3, 6, 9, 12, 18, and 24 months, focusing on nasal polyp score (NPS), symptoms, olfactory function, and quality of life (QoL). Additionally, the safety profile was evaluated by monitoring side effects and eosinophil blood count.

resultsA total of 30 patients (19 males, 11 females; mean age 53.7 years) were included. Dupilumab treatment led to significant clinical improvements, including a reduction in NPS, relief of nasal symptoms, and notable improvements in olfactory function and QoL, as demonstrated through SNOT-22 and VAS scores. Twenty-three patients (77%) achieved disease remission.

conclusionThis retrospective study confirms the efficacy of Dupilumab in managing difficult-to-treat, type-2 inflammation-driven CRSwNP, with a high percentage of patients achieving remission. Further studies with larger cohorts along with universal guidelines establishing validated criteria, including specific cut-off values, for a standardized definition of remission in CRSwNP are required.

Indexed as

Antibodies, Monoclonal, HumanizedBiological ProductsNasal PolypsRhinitisSinusitisAdultAgedChronic DiseaseFemaleHumansMaleMiddle AgedQuality of LifeRemission InductionRetrospective StudiesRhinosinusitisAntibodies, Monoclonal, HumanizedBiological ProductsdupilumabBiologic therapyChronic rhinosinusitis with nasal polypsCRSwNPDupilumab.Real-life evidenceRemission

Identifiers

PMID40759784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.